MS and Demyelinating Disorders

The field of MS is shifting focus to issues such as understanding and tracking disease progression, approaches to treatment initiation, and the roles of diet and exercise in pathogenesis and disease course.

Discussing newer treatment options in the MS field, the staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic noted that patient preference can play a part in the decision-making process. [WATCH TIME: 3 minutes]

In cognitively impaired vs unimpaired patients, investigators found functional connectivity decreases in DMNa and DMNp and increases in the right and left frontoparietal networks.

The staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed emerging treatments in the MS field. [WATCH TIME: 2 minutes]

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed when clinicians should anticipate new therapies to treat progressive MS. [WATCH TIME: 2 minutes]

Here's what is coming soon to NeurologyLive®.

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

Chaired by Jennifer Graves, MD, PhD, MAS, the presentations also feature UC San Diego Health experts Jenelle Raynowska, MD; Jennifer Yang, MD; and Anastasie Dunn-Pirio, MD. [WATCH TIME: 1 hour, 23 minutes]

Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising results from ECTRIMS, which found no evidence of wearing off with ocrelizumab (Ocrevus; Genentech).

The postdoctoral scholar at the University of Iowa commented on why the multiple sclerosis field should lean on registered dietitians to help alleviate symptoms of patients with multiple sclerosis. [WATCH TIME: 2 minutes]

Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]

The postdoctoral scholar at the University of Iowa discussed the importance of understanding more about the effects of diet and how it is managed when caring for a patient with multiple sclerosis. [WATCH TIME 3 minutes]

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, University of Michigan Medicine, spoke to the benefits of a multifaceted approach to managing fatigue for patients with multiple sclerosis.

The associate professor of Physical Medicine & Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine discussed challenges when addressing fatigue, as well as the need to integrate digital tools for patients with MS. [WATCH TIME: 4 minutes]

Robert Zivadinov, MD, PhD, provided insight on the different components that need to be addressed to help stop—and potentially reverse—neurodegeneration in MS.

Here's what is coming soon to NeurologyLive.

The associate professor of Physical Medicine & Rehabilitation and nonclinical research psychologist at University of Michigan Medicine discussed the complexities of fatigue as a symptom following her presentation at CMCS 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.

The founder and CEO of Joi Wellness Group Multiple Sclerosis Center described motivations behind the evaluation of ocrelizumab (Ocrevus; Genentech) in minority populations with multiple sclerosis.

Outlining the development of the CHIMES trial in multiple sclerosis, the founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center spoke on tactics to get underrepresented populations involved. [WATCH TIME: 2 minutes]

A multiple sclerosis expert gives insight on which types of investigational agents may be able to repair neurodegeneration lost from disease progression.

The founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center outlined the motivations behind the trial, as well as potential reasons for underrepresentation. [WATCH TIME: 2 minutes]

Robert Zivadinov, MD, PhD, provides thoughts on hurdles of conducting clinical trials that incorporate imaging techniques sensitive and specific to myelin for patients with multiple sclerosis.